Literature DB >> 32275806

Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer.

Ming Yin1, Petros Grivas2,3, Qi-En Wang1, Amir Mortazavi1, Hamid Emamekhoo4, Sheldon L Holder5, Joseph J Drabick5, Michele Sue-Ann Woo6, Sumanta Pal7, Monali Vasekar5, Edmund Folefac1, Steven K Clinton1, Paul Monk1, Monika Joshi5.   

Abstract

BACKGROUND: DNA damage response (DDR) genomic alterations may play an important role in clinical outcomes of patients with urothelial cancer (UC). However, data on the prognostic role of DDR gene alterations in patients with advanced UC remain unclear.
MATERIALS AND METHODS: We retrospectively collected data of three independent patient cohorts with relapsed or advanced UC including 81 and 91 patients from four institutions who underwent FoundationOne genomic sequencing as well as 129 patients selected from The Cancer Genome Atlas bladder cohort. Fisher's exact test was used to determine differences of mutation frequency among the three cohorts. Logistic regression analysis was performed to calculate odds ratio (OR) and 95% confidence interval (CI). Overall survival (OS) was measured from time of initial diagnosis and Cox proportional hazard regression analysis was performed to calculate the hazard ratio (HR) and 95% CI.
RESULTS: DDR genomic alterations were present in 76.5% (62/81), 40.7% (37/91), and 51.2% (66/129) of the three cohorts. ATM alterations consistently correlated with significantly shorter OS, whereas other DDR alterations (excluding ATM) were associated with better prognosis. In 152 patients treated with platinum pooled from the three cohorts, the prognostic value of alterations in ATM as compared with other predefined DDR genes was substantially different (ATM: adjusted HR [HR], 2.03; 95% CI, 1.03-4; p = .04; other DDR: adjusted HR, 0.49; 95% CI, 0.31-0.8; p = .003).
CONCLUSIONS: Genomic alterations in ATM and other DDR genes may have opposite prognostic value in relapsed and/or advanced UC. ATM may have a complex role in UC progression. IMPLICATIONS FOR PRACTICE: Somatic mutations of DNA damage response (DDR) genes are frequently found in urothelial cancer and appear to play an important role in tumorigenesis, progression, treatment response, and outcomes. In a set of DDR genes, ATM alterations were associated with worse survival, while other alterations were associated with better survival in advanced urothelial cancer. The results of this study suggest a complex role of ATM in tumor progression and call for further studies to determine the underlying mechanisms and biomarker clinical utility. © AlphaMed Press 2020.

Entities:  

Keywords:  ATM; Bladder cancer; DNA repair; Genomic alterations; Prognosis

Mesh:

Year:  2020        PMID: 32275806      PMCID: PMC7418353          DOI: 10.1634/theoncologist.2019-0851

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  19 in total

1.  Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.

Authors:  Kathryn P Pennington; Tom Walsh; Maria I Harrell; Ming K Lee; Christopher C Pennil; Mara H Rendi; Anne Thornton; Barbara M Norquist; Silvia Casadei; Alexander S Nord; Kathy J Agnew; Colin C Pritchard; Sheena Scroggins; Rochelle L Garcia; Mary-Claire King; Elizabeth M Swisher
Journal:  Clin Cancer Res       Date:  2013-11-15       Impact factor: 12.531

2.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

Review 3.  DNA damage response--a double-edged sword in cancer prevention and cancer therapy.

Authors:  Hui Tian; Zhen Gao; HuiZhong Li; BaoFu Zhang; Gang Wang; Qing Zhang; DongSheng Pei; JunNian Zheng
Journal:  Cancer Lett       Date:  2014-12-17       Impact factor: 8.679

4.  Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway.

Authors:  Deborah Chirnomas; Toshiyasu Taniguchi; Michelle de la Vega; Ami P Vaidya; Maria Vasserman; Anne-Renee Hartman; Richard Kennedy; Rosemary Foster; Jennifer Mahoney; Michael V Seiden; Alan D D'Andrea
Journal:  Mol Cancer Ther       Date:  2006-04       Impact factor: 6.261

5.  DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.

Authors:  Min Yuen Teo; Richard M Bambury; Emily C Zabor; Emmet Jordan; Hikmat Al-Ahmadie; Mariel E Boyd; Nancy Bouvier; Stephanie A Mullane; Eugene K Cha; Nitin Roper; Irina Ostrovnaya; David M Hyman; Bernard H Bochner; Maria E Arcila; David B Solit; Michael F Berger; Dean F Bajorin; Joaquim Bellmunt; Gopakumar Iyer; Jonathan E Rosenberg
Journal:  Clin Cancer Res       Date:  2017-01-30       Impact factor: 12.531

6.  ATM down-regulation is associated with poor prognosis in sporadic breast carcinomas.

Authors:  R C Bueno; R A Canevari; R A R Villacis; M A C Domingues; J R F Caldeira; R M Rocha; S A Drigo; S R Rogatto
Journal:  Ann Oncol       Date:  2013-11-26       Impact factor: 32.976

7.  The combined status of ATM and p53 link tumor development with therapeutic response.

Authors:  Hai Jiang; H Christian Reinhardt; Jirina Bartkova; Johanna Tommiska; Carl Blomqvist; Heli Nevanlinna; Jiri Bartek; Michael B Yaffe; Michael T Hemann
Journal:  Genes Dev       Date:  2009-07-16       Impact factor: 11.361

8.  ATM/RB1 mutations predict shorter overall survival in urothelial cancer.

Authors:  Ming Yin; Petros Grivas; Hamid Emamekhoo; Prateek Mendiratta; Siraj Ali; JoAnn Hsu; Monali Vasekar; Joseph J Drabick; Sumanta Pal; Monika Joshi
Journal:  Oncotarget       Date:  2018-03-30

9.  Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition.

Authors:  Ronan Russell; Lukas Perkhofer; Stefan Liebau; Qiong Lin; André Lechel; Fenja M Feld; Elisabeth Hessmann; Jochen Gaedcke; Melanie Güthle; Martin Zenke; Daniel Hartmann; Guido von Figura; Stephanie E Weissinger; Karl-Lenhard Rudolph; Peter Möller; Jochen K Lennerz; Thomas Seufferlein; Martin Wagner; Alexander Kleger
Journal:  Nat Commun       Date:  2015-07-29       Impact factor: 14.919

Review 10.  Bladder cancer stem cells: clonal origin and therapeutic perspectives.

Authors:  Yi Li; Kaisu Lin; Zhao Yang; Ning Han; Xiaofang Quan; Xiangyang Guo; Chong Li
Journal:  Oncotarget       Date:  2017-07-08
View more
  5 in total

1.  The interplay of cell cycle and DNA repair gene alterations in upper tract urothelial carcinoma: predictive and prognostic implications.

Authors:  Panagiotis J Vlachostergios
Journal:  Precis Clin Med       Date:  2020-06-03

2.  Prognostic Analysis of Differentially Expressed DNA Damage Repair Genes in Bladder Cancer.

Authors:  Yong Yang; Jieqing Yu; Yuanping Xiong; Jiansheng Xiao; Daofeng Dai; Feng Zhang
Journal:  Pathol Oncol Res       Date:  2022-05-24       Impact factor: 2.874

Review 3.  Tumor heterogeneity and the potential role of liquid biopsy in bladder cancer.

Authors:  Hai-Ming Huang; Hai-Xia Li
Journal:  Cancer Commun (Lond)       Date:  2020-12-30

4.  Identification of a Nuclear Mitochondrial-Related Multi-Genes Signature to Predict the Prognosis of Bladder Cancer.

Authors:  Xuewen Jiang; Yangyang Xia; Hui Meng; Yaxiao Liu; Jianfeng Cui; Huangwei Huang; Gang Yin; Benkang Shi
Journal:  Front Oncol       Date:  2021-10-06       Impact factor: 6.244

Review 5.  Current Perspectives on Immunotherapy in the Peri-Operative Setting of Muscle-Infiltrating Bladder Cancer.

Authors:  Paolo Andrea Zucali; Nadia Cordua; Federica D'Antonio; Federica Borea; Matteo Perrino; Fabio De Vincenzo; Armando Santoro
Journal:  Front Oncol       Date:  2020-10-21       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.